When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in ...

The Biogen/Dayra partnership is driven by the strategic potential of oral macrocyclic peptides. This emerging therapeutic approach aims to deliver biologic-like efficacy and safety in a convenient ...

Before market open, Biogen divulged in a regulatory filing that it expects to record $34 million in pre-tax expenses in its ...

Biogen said on Monday that it expects Q1 GAAP and non-GAAP net income per diluted share to be impacted by ~$0.19 per share. The charge arises from acquired in-process research and development, upfront ...

(RTTNews) - Biogen Inc. (BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company, announced Tuesday a strategic collaboration to develop select novel RNAi therapies. Through the ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESAIY) announced the rolling submission of a marketing application to receive an FDA label expansion for a subcutaneous autoinjector that delivers their Alzheimer ...

Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives March 31, 2026 8:30 AM EDTCompany ParticipantsTim Power - ...

UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab ...

Biogen is counting on its Alzheimer’s drug, Leqembi, to jumpstart growth -- and sales are progressing in the United States. But European regulators consider the drug too risky. To boost growth, Biogen ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's accelerated approval process, and is using treatments from Sarepta Therapeutics ...